ESTROGENS, PROGESTERONE, AND ENDOMETRIAL CANCER

被引：64

作者：

JICK, SS ^{[1
]}

WALKER, AM ^{[1
]}

JICK, H ^{[1
]}

机构：

[1] BOSTON UNIV,SCH MED,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,BOSTON,MA 02118

来源：

EPIDEMIOLOGY | 1993年 / 4卷 / 01期

关键词：

ESTROGENS; CONJUGATED ESTROGENS; MEDROXYPROGESTERONE ACETATE; ENDOMETRIAL NEOPLASMS; CASE-CONTROL STUDIES;

D O I：

10.1097/00001648-199301000-00005

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

We conducted a case-control study to evaluate the effect of replacement estrogen use alone, and the combined effect of estrogen and progesterone use, on the risk for endometrial cancer. We studied women age 50-64 years at Group Health Cooperative of Puget Sound. We identified 172 incident cases of endometrial cancer diagnosed during the years 1979-1989, and controls of similar age and duration of membership in the plan. Women who had used conjugated estrogens alone for 5 or more years were at increased risk for developing endometrial cancer compared with nonusers [adjusted rate ratio (RR) = 22.0; 95% confidence interval (CI) = 6.574.1]. Users of unopposed estrogens of 3-4 years' duration had a relative risk of 1.9 (95% CI = 0.4-8.7). Women who had used medroxyprogesterone acetate in combination with the estrogen therapy for 3 or more years had a risk near that of nonusers (adjusted RR = 1.3; 95% CI = 0.5-3.4) and that of users of unopposed estrogens for less than 5 years. There were insufficient women who used estrogen and progesterone together for 5 or more years to derive a separate risk estimate for these women.

引用

页码：20 / 24

页数：5

共 23 条

[1]

Burke L.B., Crosby D.L., Lao C.H., Estrogen Prescribing in Menopause, (1977)

[2]

Jick H., Watkins N.W., Hunter J.R., Dinan B.J., Madsen S., Rothman K.J., Walker A.M., Replacement estrogens and endometrial cancer, N Engl J Med, 300, pp. 218-222, (1979)

[3]

Austin D.F., Roe K.M., The decreasing incidence of endometrial cancer: Public health implications, Am J Public Health, 72, pp. 65-68, (1982)

[4]

Jick H., Walker A.M., Rothman K.J., The epidemic of endometrial cancer: A commentary, Am J Public Health, 70, pp. 264-267, (1980)

[5]

Ziel H.K., Finkle W.D., Increased risk of endometrial carcinoma among users of conjugated estrogens, N Engl J Med, 293, pp. 1167-1170, (1975)

[6]

Smith D.C., Prentice R., Thompson D.J., Herrmann W.L., Association of exogenous estrogen and endometrial carcinoma, N Engl J Med, 293, pp. 1164-1167, (1975)

[7]

Mack T.M., Pike M.C., Henderson B.E., Pfeffer R.I., Gerkins V.R., Arthur M., Brown S.E., Estrogens and endometrial cancer in a retirement community, N Engl J Med, 294, pp. 1262-1267, (1976)

[8]

Antunes C.M.F., Stolley P.D., Rosenshein N.B., Davies J.L., Tonascia J.A., Brown C., Burnett L., Rutledge A., Pokempner M., Garcia R., Endometrial cancer and estrogen use: Report of a large case-control study, N Engl J Med, 300, pp. 9-13, (1979)

[9]

Hulka B.S., Fowler W.C., Kaufman D.G., Grimson R.C., Greenberg B.G., Hogue C.J.R., Berger G.S., Pulliam C.C., Estrogen and endometrial cancer: Cases and two control groups from North Carolina, Am J Obstet Gynecol, 137, pp. 92-101, (1980)

[10]

Shapiro S., Kaufman D.W., Slone D., Rosenberg L., Miettinen O.S., Stolley P.D., Rosenshein N.B., Watring W.G., Leavitt T., Knapp R.C., Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium, N Engl J Med, 303, pp. 485-489, (1980)

← 1 2 3 →